Drug Profile
Iodine-123 MNI 672
Alternative Names: I-23-labelled MNI-672; Iodine-123-labelled MNI-672Latest Information Update: 28 May 2018
Price :
$50
*
At a glance
- Originator Molecular NeuroImaging
- Class Radiopharmaceutical diagnostics
- Mechanism of Action Single-photon emission-computed tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 May 2018 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis) in USA (IV, Injection)
- 16 May 2016 Phase-I development is ongoing in USA
- 01 Apr 2015 Molecular NeuroImaging completes a phase I trial in Alzheimer's disease (Diagnosis) in USA (IV)